Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.54 |
| ▸ | CA2 | P00918 | 11/20 | 0.54 |
| ▸ | CA9 | Q16790 | 11/20 | 0.54 |
| ▸ | CA12 | O43570 | 8/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.54 |
| ▸ | LGALS3 | P17931 | 9/20 | 0.49 |
| ▸ | LGALS1 | P09382 | 6/20 | 0.49 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23235342 | 1.00 | CA1 (0.54) | CA1CA2CA9CA12CA14 | |
| SCHEMBL21756520 | 0.96 | CA1 (0.56) | CA1CA2CA9CA12CA14 | |
| SCHEMBL29842204 | 0.96 | CA1 (0.56) | CA1CA2CA9CA12CA14 | |
| SCHEMBL22979569 | 0.87 | CA1 (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL22004612 | 0.87 | CA1 (0.58) | CA1CA2CA9CA12CA14 | |
| SCHEMBL176226 | 0.87 | CA1 (0.56) | CA1CA2CA9CA12CA14 | |
| SCHEMBL23950966 | 0.87 | CA1 (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL22981049 | 0.87 | CA1 (0.47) | CA1CA2CA9CA12CA14 | |
| SCHEMBL29698543 | 0.87 | CA1 (0.47) | CA1CA2CA9CA12CA14 | |
| Hydrochloric Acid SCHEMBL28383444 | 0.87 | CA1 (0.57) | CA1CA2CA9CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323991-A1 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323991-A1 | TETRAHYDROPYRAN-BASED THIODISACCHARIDE MIMICS AS GALECTIN-3 INHIBITORS | LGALS3, LGALS1, LGALS3BP | CA1 560/4885CA2 993/4885CA9 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.